Singulex, Inc.

University of California

Guava Technologies, Inc.

Emd Millipore Corporation

Millipore Corporation

Novilux, LLC

Luminex Corporation

Philippe J Goix

Richard A Livingston

Robert Puskas

Douglas Held

John Allan Todd

Allan H B Wu

Paul James Lingane

Kenneth F Uffenheimer

Janette T Phi-Wilson

Sara Jane Le

Alan Wu

John Todd

Janette T Phil-Wilson

Alan H Wu

Paul J Lingane

The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

Highly sensitive system and method for analysis of troponin

The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin, Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

Disclosed are methods, kits, and compositions for the highly sensitive detection of molecules. The methods, kits, and compositions are useful in determining concentrations of molecules in samples to levels of 1 femtomolar, 1 attomolar, or lower. The methods, kits, and compositions also allow the determination of concentration over a wide range, e.g., 7-log range, without need for sample dilution.

Methods and compositions for highly sensitive detection of molecules

Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNF&#x3b1;, IL-17) biomarkers provided a sensitivity of 94% for association with CHF.

Highly sensitive biomarker panels

The invention encompasses analyzers and analyzer systems that include a single particle analyzer, methods of using the analyzers and analyzers systems to analyze samples, either for single particles, e.g., protein molecules, or for multiple particles (multiplexing), methods of doing business based on the use of the analyzers or analyzer systems of the system, and electronic media for storing parameters useful in the analyzers and analyzer systems of the invention.

Method of analysis for determining a specific protein in blood samples using fluorescence spectrometry

A particle analyzer in which tagged particles to be analyzed are drawn through a suspended capillary tube where a predetermined volume in the capillary tube is illuminated. The illumination scattered by said particles is detected by a detector to count all particles. The fluorescent illumination emitted by tagged particles is detected and the output signals from the fluorescent detectors and scatter detector are processed to provide an analysis of the particles.

Particle or cell analyzer and method

Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNF&#x3b1;, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF.

Growing community of inventors

Oakland, CA, United States of America

Philippe J Goix